First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.-论文-万方医学网

作者： Michael,Staehler ^[1] ; Andrej,Panic ^[2] ; Peter J,Goebell ^[3] ; Marie,Merling ^[4] ; Karin,Potthoff ^[5] ; Edwin,Herrmann ^[6] ; Patrick,de Geeter ^[7] ; Corinne,Vannier ^[8] ; Cathrin,Hogrefe ^[5] ; Norbert,Marschner ^[5] ; Viktor,Grünwald ^[9]

作者单位： Department of Urology, Interdisciplinary Center of Renal Tumors, Ludwig-Maximilians-University of Munich, Munich, Germany. ^[1] Department of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany. ^[2] Ambulatory Uro-Oncological Therapy Unit Erlangen (AURONTE), Department of Urology and Clinic for Haematology and Oncology, University Hospital Erlangen, Erlangen, Germany. ^[3] Department of Biostatistics, iOMEDICO, Freiburg im Breisgau, Germany. ^[4] Medical Department, iOMEDICO, Freiburg im Breisgau, Germany. ^[5] Department of Urology, University Hospital Muenster, Muenster, Germany. ^[6] Outpatient-Centre for Urology "Die Urologen am Ring", Muenster, Germany. ^[7] Department of Urology, Hospital of Kassel, Kassel, Germany. ^[8] Outpatient-Centre for Interdisciplinary Oncology and Haematology, Freiburg im Breisgau, Germany. ^[9] Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, University Hospital Hannover Medical School, Hannover, Germany. ^[10] Internal Medicine (Tumour Research) and Clinic for Urology, West German Cancer Center, Essen University Hospital, Essen, Germany. ^[11]

主题词投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);血管生成抑制剂(Angiogenesis Inhibitors);癌, 肾细胞(Carcinoma, Renal Cell);腹泻(Diarrhea);疲劳(Fatigue);女(雌)性(Female);人类(Humans);甲状腺功能减退症(Hypothyroidism);吲唑类(Indazoles);Kaplan-Meiers评估(Kaplan-Meier Estimate);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);恶心(Nausea);肿瘤转移(Neoplasm Metastasis);嘧啶类(Pyrimidines);磺胺类(Sulfonamides);治疗结果(Treatment Outcome)

DOI 10.1002/ijc.33238

PMID 32738823

发布时间 2021-07-12

检索历史清除

First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.

International journal of cancer

相似文献

International journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.

International journal of cancer

相似文献

International journal of cancer

相关期刊

检索历史清除